High‐dose colchicine vs placebo
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 3.21 [2.01, 5.11]2 studies · 124 participantsLow
Findings
What do systematic reviews say?
13 questions · 13 findings · 10 reviews · Musculoskeletal
No studies found 1 · 7.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 46.2%Moderate 4 · 30.8%High 2 · 15.4%
Low‐dose colchicine vs placebo
Total adverse events · acute gout
Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.32 [0.68, 2.56]1 study · 103 participantsLow
Monthly pegloticase vs placebo
Total adverse events · participants with tophi in gout
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.05 [0.98, 1.14]1 study · 127 participantsModerate
Pegloticase every two weeks (biweekly) vs placebo
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.99 [0.91, 1.07]1 study · 128 participantsModerate
NSAIDs vs placebo
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.85]Studies not reportedLow
Nefopam 60 mg tds vs placebo
Total adverse events · patients with pain management in rheumatoid arthritis
Nefopam 60 mg tds may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 4.11 [1.58, 10.69]2 studies · 104 participantsLow
Oromucosal cannabis (Sativex) vs placebo
Total adverse events · patients with pain management in rheumatoid arthritis
Oromucosal cannabis (Sativex) may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.82 [1.1, 3]1 study · 58 participantsLow
Paracetamol vs placebo
Total adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in total adverse events: number experiencing 24 weeks compared with placebo (high certainty).
1 finding from 1 review
- RR 1.01 [0.92, 1.11]8 studies · 3252 participantsHigh
Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic
Total serious adverse events · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic showed no clear difference in total serious adverse events compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
- RR 1.05 [0.87, 1.28]6 studies · 3151 participantsModerate
Corticosteroids (dexamethasone) vs placebo
Total adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
- no estimate extracted1 study · 49 participantsLow
Antidepressants vs placebo
Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
- RR 1.27 [1.15, 1.41]9 studies · 2101 participantsHigh
Sulfasalazine vs placebo
Withdrawals due to adverse events · Patients with ankylosing spondylitis
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.43 [1.04, 1.94]11 studies · 895 participantsModerate
Diacerein vs placebo
Total number of serious adverse events not measured · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found